A selective reversible monoamine oxidase B inhibitor in smoking cessation: effects on its own and in association with transdermal nicotine patch

Berlin, Ivan; Hunneyball, Ian; Greiling, Doris; Jones, Stephen; Fuder, H.; Stahl, Henry

doi:10.1007/s00213-012-2692-2

Cited by 21 publications

(10 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have evaluated specific components of tobacco smoke for their MAO inhibiting and neuroprotective properties (Castagnoli & Murugesan, 2004;Berlin et al, 2012;Carradori et al, 2014).…”

Section: Hypotheses Of Biological Mechanismsmentioning

confidence: 99%

Association between cigarette smoking and Parkinson’s disease: A meta-analysis

Liu

et al. 2015

Archives of Gerontology and Geriatrics

136

118

View full text Add to dashboard Cite

Section: Hypotheses Of Biological Mechanismsmentioning

confidence: 99%

Association between cigarette smoking and Parkinson’s disease: A meta-analysis

Liu

et al. 2015

Archives of Gerontology and Geriatrics

136

118

View full text Add to dashboard Cite

“…Although early trials were promising , subsequent trials yielded disappointing results. Selective MAO B inhibitors, either alone or in association with the nicotine patch , did not sufficiently increase the abstinence rate in powered, randomized, placebo‐controlled trials.…”

Section: Special Populationsmentioning

confidence: 94%

Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice

Aubin

Luquiens

Berlin

2014

Brit J Clinical Pharma

Self Cite

109

View full text Add to dashboard Cite

Strategies for assisting smoking cessation include behavioural counselling to enhance motivation and to support attempts to quit and pharmacological intervention to reduce nicotine reinforcement and withdrawal from nicotine. Three drugs are currently used as first line pharmacotherapy for smoking cessation, nicotine replacement therapy, bupropion and varenicline. Compared with placebo, the drug effect varies from 2.27 (95% CI 2.02, 2.55) for varenicline, 1.69 (95% CI 1.53, 1.85) for bupropion and 1.60 (95% CI 1.53, 1.68) for any form of nicotine replacement therapy. Despite some controversy regarding the safety of bupropion and varenicline, regulatory agencies consider these drugs as having a favourable benefit/risk profile. However, given the high rate of psychiatric comorbidity in dependent smokers, practitioners should closely monitor patients for neuropsychiatric symptoms. Second-line pharmacotherapies include nortriptyline and clonidine. This review also offers an overview of pipeline developments and issues related to smoking cessation in special populations such as persons with psychiatric comorbidity and pregnant and adolescent smokers.

show abstract

“…An alveolar carbon monoxide (CO) reading of ≤6 ppm was used to confirm no recent marijuana or tobacco smoking (Cooper and Haney, 2009; Metrik et al, 2012) with a Bedfont Scientific Smokelyzer®. Tobacco smokers were permitted to smoke a tobacco cigarette following the CO test to prevent nicotine withdrawal.…”

Section: Methodsmentioning

confidence: 99%

Cue-elicited increases in incentive salience for marijuana: Craving, demand, and attentional bias

Metrik

Aston

Kahler

et al. 2016

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Background Incentive salience is a multidimensional construct that includes craving, drug value relative to other reinforcers, and implicit motivation such as attentional bias to drug cues. Laboratory cue reactivity (CR) paradigms have been used to evaluate marijuana incentive salience with measures of craving, but not with behavioral economic measures of marijuana demand or implicit attentional processing tasks. Methods This within-subjects study used a new CR paradigm to examine multiple dimensions of marijuana’s incentive salience and to compare CR-induced increases in craving and demand. Frequent marijuana users (N=93, 34% female) underwent exposure to neutral cues then to lit marijuana cigarettes. Craving, marijuana demand via a marijuana purchase task, and heart rate were assessed after each cue set. A modified Stroop task with cannabis and control words was completed after the marijuana cues as a measure of attentional bias. Results Relative to neutral cues, marijuana cues significantly increased subjective craving and demand indices of intensity (i.e., drug consumed at $0) and Omax (i.e., peak drug expenditure). Elasticity significantly decreased following marijuana cues, reflecting sustained purchase despite price increases. Craving was correlated with demand indices (r’s: 0.23–0.30). Marijuana users displayed significant attentional bias for cannabis-related words after marijuana cues. Cue-elicited increases in intensity were associated with greater attentional bias for marijuana words. Conclusions Greater incentive salience indexed by subjective, behavioral economic, and implicit measures was observed after marijuana versus neutral cues, supporting multidimensional assessment. The study highlights the utility of a behavioral economic approach in detecting cue-elicited changes in marijuana incentive salience.

show abstract

A selective reversible monoamine oxidase B inhibitor in smoking cessation: effects on its own and in association with transdermal nicotine patch

Abstract: The selective, reversible MAO-B inhibitor EVT302 was not superior to placebo in helping smokers quit, in line with data with selegiline and confirms that MAO-B inhibitors are not effective in smoking cessation. Co-administration of NP does not provide a supplementary benefit.

Cited by 21 publications

References 40 publications

Association between cigarette smoking and Parkinson’s disease: A meta-analysis

Association between cigarette smoking and Parkinson’s disease: A meta-analysis

Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice

Cue-elicited increases in incentive salience for marijuana: Craving, demand, and attentional bias

Contact Info

Product

Resources

About